Magnolia NeuroSciences
New York
About Magnolia NeuroSciences
Magnolia Neurosciences aims to discover and develop proprietary, selective, and drug-like small molecule therapeutics for the prevention of neuronal cell death, thereby providing novel treatment options for patients suffering from neurodegeneration and related conditions. Magnolia Neurosciences Corporation, created to pursue technologies developed at The University of Texas MD Anderson Cancer Center’s Therapeutics Discovery Division and the Neurodegeneration Consortium (NDC), is a New York-based Accelerator Life Science Partner portfolio company.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $49.4M
- Last round: Series Unknown (Jul 2020)
- Website: magnolianeurosciences.com
- Phone: 646-828-5990
Industries & Categories
Biotechnology, Health Care, Neuroscience, Wellness
Social Profiles
Canonical: https://fsome.com/organization/magnolia-neurosciences-45391 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.